The Pharmaceutical Benefits
Advisory Committee (PBAC)
has released its March
recommendations, including
the listing of intrauterine
Levonorgestrel 13.5 mg as a
restricted benefit for contraception,
as well as a change to the listing of
varenicline for smoking cessation
to allow an extra course within 12
months for those unsuccessful in
quitting during or after a course of
PBS subsidised varenicline.
The PBAC said the latter
was based on acceptable cost
effectiveness to placebo, bupropion
and nicotine replacement therapy
(NRT), was of “superior efficacy”
to all three and was “no worse” in
terms of safety to bupropion (but
was inferior to placebo and NRT).
To read more, CLICK HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 29 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Apr 14
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.